Moderna, Inc. — Director's Dealing 2021

Aug 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2021-08-05

Reporting Person: Burton Paul (Chief Medical Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$416.26	2031-08-05	Common Stock (15002)	15002	Direct
Restricted Stock Units	$0		Common Stock (6438)	6438	Direct
Restricted Stock Units	$0		Common Stock (3219)	3219	Direct

Footnotes

F1: 25% of this option will vest and become exercisable on August 5, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F2: 25% of the shares subject to this restricted stock unit award will vest on August 5, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F3: The shares subject to this restricted stock unit award will vest in full on August 5, 2024, subject to the recipient's continued service.